{
    "clinical_study": {
        "@rank": "78793", 
        "acronym": "Neurepo", 
        "arm_group": [
            {
                "arm_group_label": "Erythropoietin beta", 
                "arm_group_type": "Active Comparator", 
                "description": "1000 to 1500 U/kg/dose X 3 every 24 hours"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "0.2 ml saline solution X 3 given every 24 hours"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the efficacy of high dose Erythropoietin to\n      improve survival and neurologic outcome in asphyxiated term newborn undergoing cooling."
        }, 
        "brief_title": "Efficacy of Erythropoietin to Improve Survival and Neurological Outcome in Hypoxic Ischemic Encephalopathy", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Hypoxic Ischemic Encephalopathy", 
        "condition_browse": {
            "mesh_term": [
                "Hypoxia-Ischemia, Brain", 
                "Hypoxia, Brain", 
                "Brain Ischemia", 
                "Ischemia", 
                "Brain Damage, Chronic", 
                "Delirium", 
                "Encephalitis", 
                "Hepatic Encephalopathy", 
                "Neurotoxicity Syndromes"
            ]
        }, 
        "detailed_description": {
            "textblock": "Hypoxic-ischemic encephalopathy remains the main cause of death or long term neurologic\n      impairments in neonates. Yet, therapies for birth asphyxia are currently limited.\n      Hypothermia when applied within 6 hours after birth demonstrate partial improvement in\n      outcome of newborns specially those with moderate form. Erythropoietin and its receptors are\n      upregulated after brain injury in ischemic conditions. Systemically administered\n      erythropoietin is neuroprotective in animal models of birth asphyxia. To date, one study\n      demonstrate improvement neurologic outcome in asphyxiated term newborn under erythropoietin\n      treatment but no reports evaluating beneficial of erythropoietin associated with cooling.\n      This is a large randomised controlled trial to evaluate the efficacy of high dose\n      erythropoietin on outcome at two years of asphyxiated term newborns undergoing cooling."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Term or near-term newborn  (> = 36 weeks gestational age)\n\n          -  Moderate to severe encephalopathy\n\n          -  undergoing moderate controlled hypothermia started within 6 hours after delivery\n\n          -  Beneficiary of social security plan\n\n          -  Informed consent parental authority\n\n        Exclusion Criteria:\n\n          -  Impossibility of getting controlled hypothermia before H6\n\n          -  Infant older than 12 hours of age\n\n          -  Chromosomal or significant congenital abnormality\n\n          -  Predictable surgery in the first 3 days of life\n\n          -  Uncontrolled collapse\n\n          -  Haemorrhagic syndrome unchecked\n\n          -  Head trauma with or without skull fracture"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "12 Hours", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "330", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01732146", 
            "org_study_id": "110111"
        }, 
        "intervention": [
            {
                "arm_group_label": "Erythropoietin beta", 
                "description": "erythropoietin intravenous injection (5000 U/ 0.3 ml)1000 to 1500 U/kg/dose X 3 given every 24 hours with the first dose within 12 hours of delivery", 
                "intervention_name": "erythropoietin Beta", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "0.2 ml saline solution X 3 given every 24 hours with the first dose within 12 hours of delivery"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Epoetin Alfa"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hypoxic Ischemic Encephalopathy", 
            "Term neonate", 
            "Neuroprotection", 
            "erythropoietin"
        ], 
        "lastchanged_date": "August 2, 2013", 
        "location": {
            "contact": {
                "email": "Juliana.patkai@cch.aphp.fr", 
                "last_name": "Juliana Patkai, PhD", 
                "phone": "+ 33 1 58 41 54 12"
            }, 
            "facility": {
                "address": {
                    "city": "Paris", 
                    "country": "France", 
                    "zip": "75014"
                }, 
                "name": "Cochin Hospital"
            }, 
            "investigator": {
                "last_name": "Juliana Patkai, MD, PhD", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase III Study of Efficacy of High Dose Erythropoietin to Prevent Hypoxic-ischemic Encephalopathy Sequelea in Term Newborn", 
        "overall_contact": {
            "email": "juliana.patkai@cch.aphp.fr", 
            "last_name": "Juliana Patkai, MD, PhD", 
            "phone": "+ 33 1 58 41 54 12"
        }, 
        "overall_contact_backup": {
            "email": "laurence.lecomte@nck.aphp.fr", 
            "last_name": "Laurence Lecomte, PhD", 
            "phone": ": +33 1 71 19 64 94"
        }, 
        "overall_official": {
            "affiliation": "Cochin Hospital", 
            "last_name": "Juliana Patkai, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Survival without neurologic sequelea", 
            "safety_issue": "Yes", 
            "time_frame": "at 24 months"
        }, 
        "reference": {
            "PMID": "19651565", 
            "citation": "Zhu C, Kang W, Xu F, Cheng X, Zhang Z, Jia L, Ji L, Guo X, Xiong H, Simbruner G, Blomgren K, Wang X. Erythropoietin improved neurologic outcomes in newborns with hypoxic-ischemic encephalopathy. Pediatrics. 2009 Aug;124(2):e218-26. Epub 2009 Jul 27."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01732146"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "number of dead patients", 
                "measure": "Mortality rates", 
                "safety_issue": "Yes", 
                "time_frame": "Within 24 months"
            }, 
            {
                "description": "Mental Developmental index (Brunet Lezine Test), motor, visual and hearing impairment", 
                "measure": "Rate of moderate and severe sequelae", 
                "safety_issue": "No", 
                "time_frame": "at 24 months"
            }, 
            {
                "description": "Brain MRI performed between day 6 and day 12 after birth", 
                "measure": "Aspect of brain lesions on MRI", 
                "safety_issue": "No", 
                "time_frame": "at day 6 and day 12 after birth"
            }, 
            {
                "measure": "Tolerance of treatment", 
                "safety_issue": "Yes", 
                "time_frame": "at 24 months"
            }
        ], 
        "source": "Assistance Publique - H\u00f4pitaux de Paris", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Assistance Publique - H\u00f4pitaux de Paris", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}